S-1: Bone Biologics Launches Public Offering to Fund Clinical Trials Amidst Going Concern Doubts

Bone Biologics Corporation announced a public offering of common stock and warrants to raise approximately $4.3 million, aiming to fund clinical trials and patent portfolio expansion, while acknowledging substantial doubt about its ability to continue as a going concern.

Summary

• Bone Biologics Corporation is conducting a public offering of up to 846,023 shares of common stock, Series D warrants, and Series E warrants.
• The offering also includes pre-funded warrants for investors whose beneficial ownership would exceed 4.99% (or 9.99%).
• The assumed combined public offering price is $5.91 per share and accompanying warrants, based on the Nasdaq closing price on June 20, 2025.
• The Series D Warrants have a five-year term and an exercise price of $5.91 per share, exercisable upon stockholder approval or immediately if pricing conditions are met.
• The Series E Warrants have an 18-month term and an exercise price of $5.91 per share, exercisable immediately.
• The pre-funded warrants have an exercise price of $0.001 and are immediately exercisable.
• The company expects to raise approximately $4.3 million in net proceeds from this "best efforts" offering, assuming all securities are sold and no warrants are exercised.
• Proceeds are intended for funding clinical trials, maintaining and extending the patent portfolio, and general corporate purposes.
• The company reported a net loss of $4.1 million and used $4.1 million in cash from operations for the year ended December 31, 2024.
• As of March 31, 2025, accumulated losses since inception were approximately $86.0 million, and cash was $2,746,555.
• The company's independent auditors expressed substantial doubt about its ability to continue as a going concern.
• Bone Biologics recently completed a 1-for-6 reverse stock split on June 10, 2025, to regain compliance with Nasdaq's minimum bid price rule, and believes it has regained compliance as of June 24, 2025.
• The company is a clinical-stage medical device company focused on bone regeneration using its NELL-1 protein combined with DBM (NB1) for spinal fusion.
• A first-in-human pilot clinical study for NB1 is underway in Australia, evaluating safety and effectiveness in up to 30 adult subjects undergoing transforaminal lumbar interbody fusion for degenerative disc disease.
• The company's patent portfolio consists of six patents expiring between 2026 and 2033, with plans to expand.

Sentiment

Score: 3

Explanation: The company is in a precarious financial position with an explicit 'going concern' warning from its auditors and significant accumulated losses. While there is ongoing clinical progress and a clear strategy for product development, the 'best efforts' nature of the capital raise and the immediate substantial dilution for new investors present high financial risks. The positive clinical developments are overshadowed by the severe financial instability.

Positives

• Initiation of a first-in-human pilot clinical study for NB1 in Australia, a significant step towards commercialization.
• The study design for NB1 was reviewed and agreed upon by the FDA's Division of Orthopedic Devices, supporting progression to a pivotal U.S. clinical trial.
• NELL-1 technology platform has been exclusively licensed worldwide from UCLA TDG, providing proprietary rights.
• Preclinical studies in large animals (sheep) demonstrated effective bone formation and good tolerability with rhNELL-1.
• The company has successfully surpassed four critical milestones: successful small laboratory scale pilot run for manufacturing, validated protein dosing and efficacy in large animal studies, completed pivotal animal study, and initiated first-in-human clinical study.
• The company believes NELL-1 addresses unmet clinical challenges in bone regeneration, particularly for "hard healers."
• The company has regained compliance with Nasdaq's minimum bid price rule following a reverse stock split.

Negatives

• The company has a history of recurring operating losses, with a net loss of $4.1 million and $4.1 million cash used in operations for the year ended December 31, 2024.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern.
• Current available cash is expected to fund operations only up to the fourth quarter of 2025, necessitating additional capital raises.
• The offering is a "best efforts" offering with no minimum amount, meaning the company may not raise sufficient capital to fund its business plans.
• Investors will experience immediate and substantial dilution of $0.76 per share from the offering.
• There is no established public trading market for the pre-funded warrants or the Series D and E warrants, limiting their liquidity.
• The company's common stock was recently non-compliant with Nasdaq's minimum bid price rule, requiring a reverse stock split, and there's no assurance the price will remain elevated.
• The company relies heavily on independent organizations, advisors, and consultants for critical functions like regulatory approval, clinical management, manufacturing, marketing, and sales, which may not always be available on timely or affordable terms.
• The company has only two full-time employees, indicating limited internal operational capacity.

Risks

• **Going Concern Risk**: Recurring operating losses and limited cash raise substantial doubt about the company's ability to continue as a going concern, potentially leading to loss of investment.
• **Stock Price Volatility**: The price of common stock and public warrants may fluctuate substantially due to factors like Nasdaq listing compliance, financing needs, clinical trial success/delays, safety concerns, capital structure changes, and general market conditions.
• **Future Dilution**: Future sales and issuances of common stock or equity-linked securities could result in additional dilution for existing stockholders and cause share price to fall.
• **Warrant Speculative Nature**: Warrants are speculative, do not confer common stock ownership rights until exercised, and may expire valueless if the market price does not exceed the exercise price.
• **Lack of Public Market for Warrants**: No established public trading market for pre-funded warrants or Series D/E warrants, limiting liquidity.
• **No Stockholder Rights Until Exercise**: Holders of warrants and pre-funded warrants have no rights as common stockholders until they acquire common stock upon exercise.
• **Management Discretion over Proceeds**: Management has broad discretion over the use of offering proceeds, which might not increase investment value.
• **Best Efforts Offering Risk**: No minimum offering amount means the company may not raise sufficient capital for its business plans, and investors will not receive refunds.
• **Nasdaq Delisting Risk**: Failure to comply with Nasdaq's continued listing standards (e.g., minimum bid price) could result in delisting, negatively impacting stock price and liquidity.
• **Intellectual Property Risks**: Reliance on patents and regulatory exclusivities; no assurance that patent applications will be approved, or that existing patents won't be challenged, invalidated, or circumvented. Risk of infringing on others' IP rights.
• **Limited Operating History**: Difficult to evaluate current business and future prospects due to limited operating history and minimal assets.
• **Long-Term Capital Requirements**: Substantial additional funds are needed for FDA approval and commercialization, with no assurance of availability or acceptable terms.
• **Increased Operating Expenses**: Expected increase in operating expenses makes achieving and maintaining profitability difficult.
• **Debt Incurrence Risks**: Incurring substantial debt could adversely affect financial condition by requiring significant cash flow for payments and limiting flexibility.
• **Preemptive Rights**: Preemptive rights held by CEO and CFO could deter potential investors or investment banks.
• **Penny Stock Rules**: If delisted from Nasdaq and price falls below $5.00, common stock could become subject to penny stock rules, reducing trading activity.
• **Reliance on Third Parties**: Dependence on independent organizations/consultants for critical services (regulatory, clinical, manufacturing, marketing, sales) poses risks if services are not timely or affordable.
• **Key Personnel Retention**: Losing key personnel or failing to recruit necessary additional personnel would impede development objectives.

Future Outlook

Bone Biologics plans to use the proceeds from this offering to fund ongoing clinical trials for its NB1 bone graft device, maintain and expand its patent portfolio, and for general working capital. The company anticipates completing its first-in-human pilot clinical trial in Australia 12 months after enrolling the 30th patient, with the data intended to support a future, larger U.S. pivotal clinical study for FDA Pre-Market Approval (PMA). The company expects to incur additional near-term losses and will need to raise substantial additional capital to fund future operations beyond Q4 2025.

Management Comments

• "Management believes that NELL-1 technology will perform as well as other growth factors, addressing this $8 billion global market opportunity per Fortune Business Insights."
• "Continued capital funding is critical to facilitate the development of our Nell-1 technology through the clinical regulatory path."

Industry Context

Bone Biologics operates in the medical device industry, specifically targeting bone regeneration. Its lead product candidate, NB1, aims to address challenges in orthopedic surgery, particularly spinal fusion, a segment of the global bone graft substitute market estimated at $3 billion. The company also sees potential applications in non-union trauma cases ($8 billion global market) and osteoporosis ($11.2 billion market). The company's focus on a 'target-specific' growth factor (NELL-1) aims to differentiate it from existing solutions by offering controlled bone regeneration, potentially overcoming issues like uncontrolled growth and inflammatory responses associated with current compounds. The need for FDA approval via a PMA application indicates a rigorous regulatory pathway typical for novel combination products in this space.

Comparison to Industry Standards

• The company aims for NB1 to achieve comparable efficacy and safety to autografts, which are currently considered the "gold standard" for spine fusion.
• Management believes NELL-1 technology will perform as well as other growth factors in the non-union trauma cases market.

Corporate Governance

Related Party Transactions

• Jeffrey Frelick (President and CEO) and Deina Walsh (CFO) hold contractual preemptive rights to participate in future financings to maintain their percentage interest.
• These preemptive rights have been irrevocably waived for the current public offering.

Stakeholder Impact

• **Shareholders**: Potential for significant immediate dilution ($0.76 per share) from the offering. High risk of losing all or a substantial portion of their investment due to the company's going concern status and the 'best efforts' nature of the capital raise. Limited liquidity for warrants. No cash dividends are anticipated in the foreseeable future.
• **Employees**: Potential loss of confidence and job security if the company struggles to obtain sufficient financing or faces delisting from Nasdaq, which could impede operations and development objectives.
• **Business Partners**: Risk of losing confidence from business partners if the company's financial instability or Nasdaq delisting issues persist, potentially jeopardizing ongoing collaborations and future agreements.

Next Steps

• Complete the current public offering by July 24, 2025 (unless terminated earlier).
• Fund clinical trials, maintain and extend patent portfolio, and for working capital and other general corporate purposes using offering proceeds.
• Continue the first-in-human pilot clinical study for NB1 in Australia, anticipating completion 12 months after enrolling the 30th patient.
• Use data from the Australia study to enable a future, larger U.S. pivotal clinical study.
• Seek FDA-approved pre-market approval (PMA) application for NB1 in the United States.
• Submit a patent application with the USPTO by the end of the second quarter of 2025 regarding proprietary compositions of rhNELL-1 polypeptide.
• Maintain Nasdaq listing compliance.
• Hold an annual or special meeting of stockholders on or prior to 90 days following the Closing Date for Stockholder Approval (if required by Nasdaq rules). If not obtained, call meetings every 90 days thereafter.

Key Dates

Recommendation

Keywords

Bone Regeneration, Spinal Fusion, NELL-1, Medical Device, Biologics, Clinical Stage, SEC Filing, S-1, Public Offering, Warrants, Nasdaq Listing, Biotechnology, Orthopedics, Degenerative Disc Disease, PMA Application, FDA Approval, Capital Raise, Going Concern